TUMOR NECROSIS AS A CORRELATE FOR RESPONSE IN SUBGROUP OF PATIENTS WITH ADVANCED HEPATOCELLULAR CARCINOMA (HCC) TREATED WITH SORAFENIB

被引：0
|
作者：
Abou-Alfa, G. K. [1 ]
Zhao, B. [1 ]
Capanu, M. [1 ]
Guo, P. [1 ]
Liu, F. [1 ]
Jacobs, G. [1 ]
Gansukh, B. [1 ]
Moscovici, M. [2 ]
Lentini, G. [3 ]
Schwartz, L. [1 ]
机构：
[1] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA
[2] Bayer SpA PH, Med, Milan, Italy
[3] Bayer Vital GmbH, Gi Oncol, Leverkusen, Germany
来源：
ANNALS OF ONCOLOGY | 2008年 / 19卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：178 / 178
页数：1
相关论文
共 50 条
  • [1] Influence of underlying liver disease on response to sorafenib in patients with advanced hepatocellular carcinoma (HCC)
    Bouattour, M.
    Faivre, S. J.
    Dreyer, C.
    Paradis, V.
    Raymond, E.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (04)
  • [2] A multicenter analysis of prognostic factors in patients with advanced hepatocellular carcinoma (HCC) treated with sorafenib.
    Smith, Alan D.
    Chan, Kelvin K.
    Lim, Howard John
    Cheung, Winson Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [3] SORAFENIB TREATMENT FOR HEPATOCELLULAR CARCINOMA (HCC) IN PATIENTS WITH ADVANCED LIVER DISEASE
    Alves, Rogerio C.
    Alves, Daniele E.
    Guz, Betty
    Viana, Monica V.
    Harriz, Michelle C.
    Matos, Carla A.
    Terrabuio, Deborah
    Chagas, Aline
    Moutinho, Renata D.
    Taddeo, Eliane F.
    Duarte, Kelly C.
    Oliveira, George P.
    Ribeirol, Juliana M.
    Kondo, Mario
    Gampel, Otavio
    Poletti, Paula
    HEPATOLOGY, 2010, 52 (04) : 1193A - 1193A
  • [4] Outcomes and safety of sorafenib in elderly patients with advanced hepatocellular carcinoma (HCC)
    Ziogas, Dimitrios
    Thillai, Kiruthikah
    Korantzis, Ippokratis
    Chowdhury, M. H. Ruhe
    Papadatos-Pastos, Dionysios
    Suddle, Abid
    O'Grady, John
    Heaton, Nigel
    Ross, Paul J.
    Sarker, Debashis
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (03)
  • [5] Biomarkers of Apoptosis and Necrosis in Patients with Hepatocellular Carcinoma Treated with Sorafenib
    Godin, Corinne
    Louandre, Christophe
    Bodeau, Sandra
    Diouf, Momar
    Saidak, Zuzana
    Conte, Marie-Alix
    Chauffert, Bruno
    Barbare, Jean-Claude
    Barget, Nathalie
    Trinchet, Jean-Claude
    Ganne, Nathalie
    Galmiche, Antoine
    ANTICANCER RESEARCH, 2015, 35 (03) : 1803 - 1808
  • [6] Outcomes and safety of sorafenib in elderly patients with advanced hepatocellular carcinoma (HCC)
    Ziogas, Dimitris
    Thillai, Kiruthikah
    Papadatos-Pastos, Dionysios
    Chowdhury, Mahfuja Hussain Ruhe
    Korantzis, Ippokratis
    Manickavasagar, Thubeena
    Suddle, Abid
    O'Grady, John
    Heaton, Nigel
    Ross, Paul J.
    Sarker, Debashis
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [7] Prospective evaluation of the factors predicting the prognosis of advanced hepatocellular carcinoma (HCC) patients treated with sorafenib.
    Adachi, Takuya
    Nouso, Kazuhiro
    Miyahara, Koji
    Dohi, Chihiro
    Wada, Nozomu
    Takeuchi, Yasuto
    Kuwaki, Kenji
    Onishi, Hideki
    Ikeda, Fusao
    Nakamura, Shinichiro
    Shiraha, Hidenori
    Takaguchi, Koichi
    Uematsu, Shuji
    Iwadou, Shouta
    Takuma, Yoshitaka
    Hagihara, Hiroaki
    Takabatake, Hiroyuki
    Takaki, Akinobu
    Okada, Hiroyuki
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [8] Usefulness of alpha-fetoprotein response in patients treated with sorafenib for advanced hepatocellular carcinoma
    Personeni, Nicola
    Bozzarelli, Silvia
    Pressiani, Tiziana
    Rimassa, Lorenza
    Tronconi, Maria Chiara
    Sclafani, Francesco
    Carnaghi, Carlo
    Pedicini, Vittorio
    Giordano, Laura
    Santoro, Armando
    JOURNAL OF HEPATOLOGY, 2012, 57 (01) : 101 - 107
  • [9] Prognostic factors in patients with advanced hepatocellular carcinoma treated with sorafenib
    Pinter, M.
    Sieghart, W.
    Hucke, F.
    Graziadei, I.
    Vogel, W.
    Maieron, A.
    Koenigsberg, R.
    Weissmann, A.
    Kornek, G.
    Matejka, J.
    Stauber, R.
    Buder, R.
    Gruenberger, B.
    Schoeniger-Hekele, M.
    Mueller, C.
    Peck-Radosavljevic, M.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2011, 34 (08) : 949 - 959
  • [10] A phase I study of bavituximab and sorafenib in patients with advanced hepatocellular carcinoma (HCC)
    Yopp, Adam
    Arriega, Yuii
    Singal, Amit
    Mansour, John
    Bach, Glen
    Thorpe, Phillip
    CANCER RESEARCH, 2012, 72
12345